Pharmaceutical industry oral dosage forms

The pharmaceutical industry directs considerable effort toward maximizing the usefulness and reliability of oral dosage forms in an effort to minimize the need for parenteral administration. Factors that... 

Food and Drug Administration CDER, Guidance for industry waiveinofivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a bio pharmaceutics classi cation system, 2000. 

Softgel capsules have gained popularity and use in the pharmaceutical industry for human and veterinary use, as an oral dosage form, as suppositories for rectal and vaginal administration, single... 

Another professional organization headquartered in central Europe, APV (International Association for Pharmaceutical Technology, Mainz, Germany), developed the topic further in two seminars in Gelsenkirchen in late 1981 and early 1982 [6]. Speakers from industry demonstrated how validation could be applied to industrial activities and how a balance between resources allocation and results could be achieved. Oral dosage forms, topicals, and sterile products, as well as analytical methods during development, transfer, and production phases were discussed. 

The pharmaceutical industry conducts dissolution testing of solid oral dosage forms to serve many purposes, including ... 

Maltitol is widely used in the pharmaceutical industry in the formulation of oral dosage forms. It is a noncariogenic bulk sweetener, approximately as sweet as sucrose, well adapted as a diluent for different oral dosage forms, wet granulation, and hard coating. 

Pharmaceutical analysis needs more functionality tests for solid oral dosage forms. After all, we know and have a record of the amount of drug added to the batch. The industry needs to take advantage of the modernization of the techniques described within and routinely apply them to in situ analyses... 

Harnessing the benefits of nanocoatings in the pharmaceutical industry is a prospect that has built momentum in recent years. Perchance this is related to the impoverished quality of coatings produced by some coating methods for oral dosage forms. 

How the product will be used by the patient or the customer—Here again our industry is so diverse that we must indicate that the limits calculated should take into account the nature of the customer. Is the customer another company that uses the product, which may be a chemical, to make another intermediate, or is the customer the patient who actually takes the product in the form of a finished pharmaceutical dosage form Is the product a sterile product and do we need to consider bacteria as a potential contaminant or is the product a nonsterile product in which bacterial contamination may be a lesser issue If the product is a finished pharmaceutical dosage form, will it be used intravenously, orally, ophthalmically, topically, rectally, vaginally, or by other means ... 

---